March 4, 2011
COLUMBUS, Ohio – Dr. Guido Marcucci (43017) has been appointed associate director of translational research for the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
In this role, Marcucci will work to accelerate translational research throughout the Ohio State cancer program. Translational research takes novel findings from basic research done in the laboratory and translates them into hypotheses that are evaluated through patient clinical trials.
Marcucci, who holds the John B. and Jane T. McCoy Chair at the OSUCCC-James, also will develop a mentorship effort that brings key basic science partners together with clinical investigators to facilitate new translational research collaborations that can lead to new and potentially improved treatment options for patients with hematological malignancies. In addition, Marcucci will help lead a project to integrate human tissue specimen data and clinical and scientific data to support the OSUCCC – James translational research mission.
Marcucci, who received his medical degree from Catholic University of the Sacred Heart in Rome, Italy, joined the OSU faculty in 1998 after completing his internal medicine internship and residency at the State University of New York, Buffalo, New York, and a two-year oncology fellowship at the Roswell Park Cancer Institution, also in Buffalo.
He is a professor of internal medicine in the division of hematology, and also is jointly appointed in Ohio State’s Department of Molecular Virology, Immunology and Medical Genetics, as well as in Ohio State’s College of Pharmacy’s Division of Pharmaceutics.
As director of the Myeloid Malignancy Program at OSUCCC – James, Marcucci focuses on drug development and the discovery of molecular prognostic biomarkers in acute myeloid leukemia, for which he is funded by the National Cancer Institute. He is chair of the Cancer and Leukemia Group B (CALGB) clinical cooperative group’s Leukemia Science Committee and the principal investigator on several CALGB and OSU clinical and correlative study protocols.
The author and coauthor of numerous manuscripts published in peer-review journals such as the New England Journal of Medicine, Cancer Cell, Journal of Clinical Investigation, Journal of Clinical Oncology and Blood, Marcucci also directs the Leukemia Tissue Bank at OSUCCC – James.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC – James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.
# # #
Eileen Scahill
Medical Center Public Affairs and Media Relations
614-293-3737
Eileen.Scahill@osumc.edu